Envoy Medical received a second notification from Nasdaq on May 19, 2026, regarding its failure to meet the $1.00 minimum bid price requirement. The company has been granted an additional 180-day compliance period, extending the deadline to November 16, 2026. To regain compliance, the Class A Common Stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The extension was granted because the company meets all other Nasdaq Capital Market listing requirements, including the market value of publicly held shares. Management has indicated a willingness to implement a reverse stock split if necessary to resolve the deficiency.